Europska Unija - hrvatski - EMA (European Medicines Agency)

ratiopharm gmbh - dcsloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminici za sistemsku primjenu, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

santen oy, niittyhaankatu 20, tampere, finska - tafluprost - kapi za oko, otopina u jednodoznom spremniku - 15 mikrograma/ml - urbroj: 1 ml kapi za oko, otopina, sadrži 15 mikrograma tafluprosta

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

santen oy, niittyhaankatu 20, tampere, finska - natrijev deksametazonfosfat levofloksacin hemihidrat - kapi za oko, otopina - 1 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 1 mg deksametazona (u obliku natrijevog deksametazonfosfata) i 5 mg levofloksacina (u obliku levofloksacin hemihidrata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

santen oy, niittyhaankatu 20, tampere, finska - dorzolamidklorid - kapi za oko, otopina - 20 mg/ml - urbroj: jedan ml otopine sadrži 20 mg dorzolamida u obliku dorzolamidklorida

Europska Unija - hrvatski - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Europska Unija - hrvatski - EMA (European Medicines Agency)

santen oy - ciklosporin - conjunctivitis; keratitis - ophthalmologicals - liječenje teških proljeće кератоконъюнктивит (ВКС) u djece s 4 godine i mlade.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastična sredstva - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

santen oy, niittyhaankatu 20, tampere, finska - tafluprost - kapi za oko, otopina - 15 mikrograma/ml - urbroj: 1 ml otopine sadrži 15 mikrograma tafluprosta

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

santen oy, niittyhaankatu 20, tampere, finska - dorzolamidklorid timololmaleat - kapi za oko, otopina - 20 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 20 mg dorzolamida u obliku dorzolamidklorida i 5 mg timololau obliku timololmaleata